

**REGISTERED COMPANY NUMBER: 04133242 (England and Wales)**  
**REGISTERED CHARITY NUMBER: 1085527**

**REPORT OF THE TRUSTEES AND**  
**UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024**  
**FOR**  
**ANAPHYLAXIS UK**

Rock Tax & Accounting  
Elm House, Tanshire Park  
Shackleford Road  
Elstead  
Godalming  
Surrey  
GU8 6LB

ANAPHYLAXIS UK

CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024

---

	Page
Report of the Trustees	1 to 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11 to 12
Cash Flow Statement	13
Notes to the Cash Flow Statement	14
Notes to the Financial Statements	15 to 23
Detailed Statement of Financial Activities	24 to 25

---

## ANAPHYLAXIS UK

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

---

#### 2024 - Expanding Reach, Deepening Impact

2024 was a year of remarkable progress for Anaphylaxis UK. Building on strong foundations, we reached more people than ever before with trusted support, practical tools and powerful awareness campaigns. Our work extended across communities, schools, workplaces, healthcare settings and international forums - always with the same goal: to improve the quality of life for everyone living with a serious allergy.

Through new partnerships, innovative resources and a growing digital presence, we deepened our impact while keeping lived experience at the heart of what we do. From the helpline to the boardroom, from classrooms to global conferences, 2024 was a year of action, connection and change.

#### Patient and Public Information & Support

In 2024, our helpline continued to be a trusted lifeline, responding to over 1,500 allergy-related queries by phone and email. Every call and email was handled with empathy, professionalism and practical advice, ensuring that patients, carers and families received timely support tailored to their needs.

Our library of factsheets, all accredited with the Patient Information Forum's PIF TICK quality mark, provided reliable, evidence-based information that was accessed more than 375,000 times this year. This recognition not only affirms our commitment to quality but also reflects the continued trust placed in our resources.

To reach audiences in new ways, we launched Let's Talk About Allergies in August - a podcast series featuring leading experts in the field. The first eight episodes, downloaded over 1,600 times, gave listeners the chance to hear directly from specialists on managing allergies and improving quality of life.

We also produced eight new patient posters focusing on practical allergy management and mental wellbeing, giving people accessible tools to manage daily life. Our new 20-member lived-experience advisory group began guiding resource creation, ensuring that our outputs remain firmly rooted in patient realities.

Regular weekly news articles covered emerging research, management tips and calls for involvement in studies - keeping our community informed and connected.

A notable highlight was our collaboration with University Hospitals Plymouth NHS Trust to produce a multimedia bee and wasp venom allergy awareness campaign, including podcasts, a mini-guide, a patient flowchart and educational posters.

#### Key achievements in 2024 :

- 1,500+ helpline enquiries supported
- 375,000+ factsheet views
- 8 podcast episodes released, 1,600+ downloads
- 8 new patient posters developed
- Established a 20-member lived-experience advisory group
- Weekly allergy news articles published
- Bee and wasp venom awareness campaign launched in partnership with NHS Plymouth

**ANAPHYLAXIS UK****REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2024**

---

**Research & Evidence Development**

We strengthened our research partnerships to advance the evidence base in allergy prevention, management and emotional support.

With the University of Southampton and Professor Graham Roberts, we continued a five-year study aimed at preventing infant food allergies, attending fortnightly project management meetings to ensure patient perspectives remained central.

Our collaboration with the University of Birmingham's FAIR study addressed inequalities in allergy management among South Asian adults, shaping surveys and targeted communication.

The University of Surrey partnership explored the psychological impact of severe allergic reactions, particularly bereavement and near-fatal anaphylaxis. This work lays the foundation for new national guidance on emotional and psychological support.

Internationally, we co-authored European consensus statements on managing allergies in schools and contributed to a global set of ten practical priorities for allergy care. Our participation in the Food Allergy in Children Priority Setting Partnership (James Lind Alliance & University of Bristol) ensured that patient needs influenced the research agenda.

**Key achievements in 2024:**

- Continued multi-year infant allergy prevention study with Southampton University
- FAIR study partnership addressing healthcare inequalities
- Service evaluation on psychological support needs with University of Surrey
- Co-authored European consensus statements on school allergy management
- Contributed to a global set of ten allergy care priorities
- Member of the Food Allergy in Children Priority Setting Partnership

**Professional Engagement & Collaboration**

Our engagement with healthcare and industry professionals deepened in 2024, helping to raise standards in allergy management across multiple sectors.

Our monthly newsletter for healthcare professionals, achieving an exceptional open rate of over 60%. At the BSACI Annual Conference, our Speaker's Corner presentations showcased the impact of AllergyWise training and audits, while our participation in the GA<sup>2</sup>FA Forum in Padua facilitated dialogue with international leaders in allergy care.

We also contributed patient insight to steering groups such as the BRIT Registry, BSACI EEDI, CYANS (Children and Young People's Allergy Network Scotland) and the Allergy in the Military group. In the food industry, we delivered allergen control training to teams at Nestlé York, bringing the human impact of allergies into focus for decision-makers.

**Key achievements in 2024:**

- Monthly healthcare newsletter launched, 60%+ open rate
  - Presentations at BSACI Annual Conference and GA<sup>2</sup>FA Forum
  - Participation in national and international steering groups
  - Industry training day with Nestlé York on allergen control
-

## ANAPHYLAXIS UK

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2024**


---

**AllergyWise Training**

AllergyWise underwent a major transformation in 2024. We introduced face-to-face training in September, visiting 21 schools, nurseries and businesses. The impact has been remarkable: 98% of attendees felt more confident in managing allergies and the same proportion reported increased confidence in using adrenaline auto-injectors.

We also redesigned the education section of our website for easier navigation and implemented automated invoicing, reducing administrative load and improving the user experience. Our e-learning courses continued to be highly valued, with 96% of school-based participants reporting improved knowledge of anaphylaxis management.

Partnerships with organisations such as SAPHNA, the National College, Twinkl and RLSS expanded our reach. The National College course alone has received 4,000+ five-star reviews.

We also collaborated with the Department for Education Early Years team to review sector resources and delivered webinars for local authorities, cementing our reputation as a trusted training provider.

**Key achievements in 2024:**

- Face-to-face AllergyWise training launched, 21 sites visited
- 98% of attendees more confident in managing allergies and using AAI's
- Education website restructure and automated invoicing
- 96% of e-learning users improved anaphylaxis knowledge
- Partnerships with SAPHNA, Twinkl, National College, RLSS and more
- 4,000+ five-star reviews for National College course

**Communications and Campaigns**

Our communications work in 2024 reached more people than ever. Website visits rose 11% to over 600,000, with total page views reaching 1.34 million. Our monthly Allergy Outlook newsletter subscriber base grew by 102% to more than 25,000, while our new Education Newsletter reached over 2,000 subscribers in its first months, with a 72% open rate.

On social media, we built a stronger and more engaged community, growing our Facebook following to 21,600, Instagram to over 9,000 and LinkedIn to over 2,200. Overall engagements across channels rose by 76%, totalling 125,000 for the year.

Our campaigns included:

- **Vegan Food Labelling Awareness** with the Food Standards Agency
- **Bee & Wasp Venom Awareness** with ALK - our 3rd most visited page of 2024
- **Anaphylaxis Awareness Week** with the launch of Hidden Battle with Allergies, highlighting the emotional impact of allergy

**Key achievements in 2024:**

- 600,000+ website visitors; 1.34 million page views
  - Newsletter subscribers up 102% to 25,000+
  - 76% increase in social media engagement
  - Successful national campaigns on vegan labelling, bee & wasp venom and emotional impact of allergies
-

**ANAPHYLAXIS UK****REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2024**

---

**Fundraising Highlights**

Fundraising in 2024 was both creative and record-breaking. Our London Marathon team raised £40,631 - the highest amount in our history. The Big Give's Christmas Challenge brought in £17,300 for Hidden Battle with Allergies, supported by corporate partners such as Fullers, Serve Legal, Boss Digital and Kitt Medical.

Our 30th anniversary "30 for 30" challenge inspired community fundraising, from school events to personal feats, raising nearly £2,000. We also received £5,000 from major donors and £30,718 through in-memoriam donations - a testament to the deep personal connection people have with our mission.

**Key achievements in 2024:**

- Record-breaking £40,631 from London Marathon team
- £17,300 raised via Big Give Christmas Challenge
- Nearly £2,000 from "30 for 30" community fundraising events
- £30,718 in in-memoriam donations
- £5,000 from major donors

**Investment performance achieved against investment objectives**

The investment objectives of the Charity are to maximise the value of reserves, while avoiding undue risk. The Charity's policy on investment includes a requirement to limit investments to 60% of liquid assets and only to invest in Funds regulated by the Financial Conduct Authority. The Charity's investments in an Income and Growth portfolio with Hargreaves Lansdown showed a gain of £10,882 on the value report at the end of December 2023 (£164,295). The value at the end of December 2024 was £175,177.

**Financial review: Reserves policy**

To achieve a sound balance between prudence and ensuring funds are expended in achieving the objectives of the Charity, the Trustees have established a policy whereby the unrestricted reserves held by the Charity should equate to at least six months operating costs. At the year end this equated to £343,181. Free reserves (excluding 6 months operating costs) at 31 December 2024 stood at £383,396.

**Restricted reserves**

Details of restricted funds are shown in note 18 of the financial statements.

**Risk review**

The Trustees have conducted a review of the major risks to which the Charity is exposed and systems have been established to manage those risks. A risk management register is maintained and risks highlighted are reviewed regularly to ensure they do not pose a threat to the Charity going forward. Key risks for the Charity include an uncertain economic outlook and its impact on fundraising by individuals and financial support from businesses.

**ANAPHYLAXIS UK****REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2024**

---

**Financial overview**

The Charity ended the year in a sound financial position with sufficient free reserves to meet its reserves policy. Net outgoing resources for the year amounted to £565,698. Unrestricted funds were £706,427 and restricted funds were £2,138.

**Financial policies**

All payments up to £10,000 made by the Charity have to be signed by two authorised signatories and by a Trustee in addition for payments over that amount. The day-to-day management of the financial affairs of the Charity is delegated to the Head of Finance and Operations who submits Management Accounts and a written report monthly to the CEO and Board of Trustees. A financial report supported by Management Accounts is delivered by the Head of Finance and Operations at each meeting of the Trustees.

**Principal funding sources**

The principal funding sources for the charity are community fundraising initiatives such as the London Marathon, sales from our AllergyWise training programme and from Business Membership. The charity also benefits from grants and sponsorship of project work such as awareness campaigns.

**Use of funds**

Funds received by the charity have contributed significantly to the expansion of services offered by the Information Team and in our ability to enhance our awareness campaigns to reach more people with allergies.

**Plans for the Future**

The Board have agreed a Strategic Framework for 2024-2028. The general impact the Anaphylaxis UK charity aims to achieve by the end of 2028 is:

We want everyone with a serious allergy to enjoy the same quality of life as someone without an allergy. Over the next five years, all of our work will focus on making this ambition a reality.

Our main priority areas and the impact we aim to achieve within each area are set out in the Business Plan since they were approved by the Board in March 2024. The main areas for future work are:

At Anaphylaxis UK, our mission remains clear and urgent: to be the leading source of trusted support, information and advocacy for people living with serious allergies. In 2024, we took significant steps forward in realising that mission - broadening our reach, deepening our impact and strengthening our voice in a world where confusion, outdated beliefs and lack of awareness about allergies still create barriers to understanding.

We know that the effects of living with a serious allergy extend well beyond the individual. Families, friends, schools, workplaces and communities all feel the impact. That is why we remain committed to delivering support that is both practical and compassionate - whether through our expanding helpline, our suite of factsheets and digital resources, or our growing network of peer support groups. In 2024, over 375,000 people accessed our information library, our helpline supported more than 1,500 individuals and our new "Let's Talk About Allergies" podcast extended our reach even further.

We continued to invest in resources that reflect the real-world challenges people face- developing posters on mental wellbeing, launching emotional support initiatives following research into bereavement and trauma and bringing lived experience into the heart of our resource development through a new advisory group.

## ANAPHYLAXIS UK

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2024**


---

This year, we also strengthened our work with professionals and businesses. Our partnerships ranged from co-authoring international consensus papers on allergy management in schools, to delivering allergy education at corporate training days with food industry leaders. We are committed to working with businesses large and small - supporting them to improve their ways of working, understand the human impact of serious allergies and implement changes that make a meaningful difference to the quality of life of their customers and employees.

Raising public awareness and addressing misunderstandings about allergy remain central to our work. Our campaigns - such as the Bee and Wasp Venom Awareness programme, the FSA-led vegan food labelling initiative and the launch of our Hidden Battle with Allergies project - have helped shine a light on issues that often go unseen. The latter highlighted the emotional toll of allergy and sparked a national conversation that we will continue to champion into 2025.

We have also significantly grown our digital presence: our website saw more than 600,000 visitors in 2024 and our newsletter subscriber base doubled to over 25,000. Social media engagement grew by over 76%, reflecting a wider community that is active, engaged and hungry for credible, practical information.

None of this would be possible without the dedicated support of our staff, whose professionalism and passion drive everything we do. Nor could we achieve this without the generosity of our donors, fundraisers, partners and volunteers. Whether through time, money, or shared expertise - your support ensures that we can continue to be a lifeline for people living with serious allergies.

Looking ahead, we will build on this foundation. We aim to grow our support networks, expand our work with businesses and ensure that people know where to turn when they need clear, reliable information and practical help. Above all, we will stay focused on improving quality of life - supporting people to manage their allergies with greater confidence and less fear.

Thank you for standing with us.

**Statement of Trustees' responsibilities**

The trustees (who are also directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.



ANAPHYLAXIS UK

REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2024

---

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**Independent Examiners**

Rock Tax & Accounting were appointed Independent Examiners at the Annual General Meeting of the Charity held on 29 August 2025.

**Structure, governance and management**

**Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**Reference and administrative details**

**Registered Company number**

04133242 (England and Wales)

**Registered Charity number**

1085527

**Registered office**

96a High Street  
Frimley  
Surrey  
GU16 7JE

**Trustees**

Dr A M Walker-Fraser Chair  
Mr P M Littleton Vice Chair  
Mrs T Randhawa  
Mrs L C Wilkinson  
Mrs S C Hall (resigned 10.4.24)  
Dr H E Evans-Howells  
Mr R J Wright KC  
Ms C C A Fearnley  
Mr J J Daley (appointed 7.6.24)

**Company Secretary**

Mrs L A Ingram

**Independent Examiner**


Chris Lowry FCA  
Rock Tax & Accounting  
Elm House, Tanshire Park  
Shackleford Road  
Elstead  
Godalming  
Surrey  
GU8 6LB

Approved by order of the board of trustees on ..... and signed on its behalf by:

ANAPHYLAXIS UK

REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 DECEMBER 2024

---

Signed by:  
  
1G4B1F0D180E469:.....  
Dr A M Walker-Fraser - Trustee

09 September 2025

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF  
ANAPHYLAXIS UK**

---

**Independent examiner's report to the trustees of Anaphylaxis UK ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed by:



1CB9094F8AEB40A...

Chris Lowry FCA

The Institute of Chartered Accountants in England and Wales

Rock Tax & Accounting  
Elm House, Tanshire Park  
Shackleford Road  
Elstead  
Godalming  
Surrey  
GU8 6LB

09 September 2025

Date: .....

## ANAPHYLAXIS UK

STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 DECEMBER 2024

		Unrestricted fund £	Restricted funds £	31.12.24 Total funds £	31.12.23 Total funds £
	Notes				
<b>Income and endowments from</b>					
Donations and legacies	2	542,265	2,138	544,403	551,512
Other trading activities	3	78,492	-	78,492	31,202
Investment income	4	10,757	-	10,757	3,383
<b>Total</b>		<u>631,514</u>	<u>2,138</u>	<u>633,652</u>	<u>586,097</u>
<b>Expenditure on</b>					
Raising funds	5	173,793	-	173,793	79,256
<b>Charitable activities</b>	6				
Charitable activities		391,691	-	391,691	496,285
Other		214	-	214	3,946
<b>Total</b>		<u>565,698</u>	<u>-</u>	<u>565,698</u>	<u>579,487</u>
Net gains on investments		<u>10,882</u>	<u>-</u>	<u>10,882</u>	<u>9,471</u>
<b>NET INCOME</b>		76,698	2,138	78,836	16,081
<b>Reconciliation of funds</b>					
Total funds brought forward		629,729	-	629,729	613,648
<b>Total funds carried forward</b>		<u><u>706,427</u></u>	<u><u>2,138</u></u>	<u><u>708,565</u></u>	<u><u>629,729</u></u>

The notes form part of these financial statements

## ANAPHYLAXIS UK

**BALANCE SHEET**  
**31 DECEMBER 2024**

	Notes	Unrestricted fund £	Restricted funds £	31.12.24 Total funds £	31.12.23 Total funds £
<b>Fixed assets</b>					
Intangible assets	12	39,330	-	39,330	37,963
Tangible assets	13	5,576	-	5,576	10,933
Investments	14	175,178	-	175,178	164,296
		<u>220,084</u>	<u>-</u>	<u>220,084</u>	<u>213,192</u>
<b>Current assets</b>					
Stocks	15	-	-	-	311
Debtors	16	201,574	-	201,574	150,045
Cash in hand		351,725	2,138	353,863	322,519
		<u>553,299</u>	<u>2,138</u>	<u>555,437</u>	<u>472,875</u>
<b>Creditors</b>					
Amounts falling due within one year	17	(66,956)	-	(66,956)	(56,338)
		<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
<b>Net current assets</b>		<u>486,343</u>	<u>2,138</u>	<u>488,481</u>	<u>416,537</u>
<b>Total assets less current liabilities</b>		<u>706,427</u>	<u>2,138</u>	<u>708,565</u>	<u>629,729</u>
<b>NET ASSETS</b>		<u><u>706,427</u></u>	<u><u>2,138</u></u>	<u><u>708,565</u></u>	<u><u>629,729</u></u>
<b>Funds</b>	18				
Unrestricted funds				706,427	629,729
Restricted funds				2,138	-
<b>Total funds</b>				<u><u>708,565</u></u>	<u><u>629,729</u></u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.


The notes form part of these financial statements

ANAPHYLAXIS UK

BALANCE SHEET - continued  
31 DECEMBER 2024

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 09 September 2025 and were signed on its behalf by:

Signed by:  
  
104B1F0D100E469:.....  
Dr A M Walker-Fraser - Trustee

## ANAPHYLAXIS UK

**CASH FLOW STATEMENT  
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Notes	31.12.24 £	31.12.23 £
<b>Cash flows from operating activities</b>			
Cash generated from operations	1	38,839	(37,824)
Net cash provided by/(used in) operating activities		38,839	(37,824)
<b>Cash flows from investing activities</b>			
Purchase of intangible fixed assets		(18,076)	(12,632)
Purchase of tangible fixed assets		(350)	(3,448)
Purchase of fixed asset investments		-	(1)
Sale of intangible fixed assets		-	2,950
Sale of tangible fixed assets		174	(2,950)
Interest received		10,757	3,383
Net cash used in investing activities		(7,495)	(12,698)
<b>Change in cash and cash equivalents in the reporting period</b>			
		31,344	(50,522)
<b>Cash and cash equivalents at the beginning of the reporting period</b>			
		322,519	373,041
<b>Cash and cash equivalents at the end of the reporting period</b>			
		353,863	322,519

The notes form part of these financial statements

## ANAPHYLAXIS UK

**NOTES TO THE CASH FLOW STATEMENT  
FOR THE YEAR ENDED 31 DECEMBER 2024**
**1. Reconciliation of net income to net cash flow from operating activities**

	<b>31.12.24</b>	<b>31.12.23</b>
	£	£
<b>Net income for the reporting period (as per the Statement of Financial Activities)</b>	78,836	16,081
<b>Adjustments for:</b>		
Depreciation charges	22,027	21,456
Gain on investments	(10,882)	(9,471)
Loss on disposal of fixed assets	214	3,946
Interest received	(10,757)	(3,383)
Decrease in stocks	311	517
Increase in debtors	(51,528)	(79,357)
Increase in creditors	10,618	12,387
<b>Net cash provided by/(used in) operations</b>	<u>38,839</u>	<u>(37,824)</u>

**2. Analysis of changes in net funds**

	<b>At 1.1.24</b>	<b>Cash flow</b>	<b>At 31.12.24</b>
	£	£	£
<b>Net cash</b>			
Cash at bank and in hand	322,519	31,344	353,863
	<u>322,519</u>	<u>31,344</u>	<u>353,863</u>
<b>Total</b>	<u>322,519</u>	<u>31,344</u>	<u>353,863</u>

The notes form part of these financial statements



## ANAPHYLAXIS UK

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**


---

**1. Accounting policies**
**Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

**Preparation of consolidated financial statements**

The financial statements contain information about Anaphylaxis UK as an individual company and do not contain consolidated financial information as the parent of a group. The charity is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Anaphylaxis UK has one subsidiary, Anaphylaxis UK Trading Ltd. The registered office of the subsidiary is 96a High Street, Frimley, Surrey GU16 7JE. Anaphylaxis UK owns 100% of the £1 ordinary share capital of the subsidiary.

The subsidiary company carries out trading activities related to the objectives of Anaphylaxis UK. All the taxable profits of the subsidiary are paid by gift to Anaphylaxis UK and are used in the furtherance of the charity's objectives. Consequently, the total reserves of the subsidiary are its £1 ordinary share capital.

Total income and expenditure of the subsidiary in the year to 31 December 2024 were £265,313 (£2023 - £264,800), including £183,240 (2023 - £258,889) paid by gift to Anaphylaxis UK.

**Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 25% on cost

**Stocks**

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

## ANAPHYLAXIS UK

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**
**1. Accounting policies - continued**
**Fund accounting**

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Hire purchase and leasing commitments**

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

**Investments**

Fixed asset investments are treated as a single asset, revalued each year to current market value.

**2. Donations and legacies**

	<b>31.12.24</b>	<b>31.12.23</b>
	<b>£</b>	<b>£</b>
Donations - members	25,304	27,638
Memoriam donations	30,718	19,828
Gift aid	37,599	27,636
Community fundraising & events	43,954	46,233
Charitable trusts and major donors	62,300	20,600
Corporate donations	11,862	7,135
Legacies	-	501
Individual membership	41,715	43,876
Professional membership	155	2,443
Other including Google Adwords	107,556	96,733
Income from subsidiary	183,240	258,889
	<u>544,403</u>	<u>551,512</u>

Since 1 January 2023 a number of activities previously undertaken by Anaphylaxis UK have been carried out by its subsidiary, Anaphylaxis UK Trading Ltd. These include corporate membership, Allergywise training, product recall work, events, special projects and some other activities. All of Anaphylaxis UK Trading Ltd's surplus for the year is gifted to Anaphylaxis UK and is included in Donations and Legacies.

**3. Other trading activities**

	<b>31.12.24</b>	<b>31.12.23</b>
	<b>£</b>	<b>£</b>
Event income	40,631	15,322
Special project income	37,500	12,380
Other sundry income	361	-
Corporate sponsorship	-	3,500
	<u>78,492</u>	<u>31,202</u>

## ANAPHYLAXIS UK

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**4. Investment income**

	<b>31.12.24</b>	<b>31.12.23</b>
	£	£
Dividends and interest rec'd	10,757	3,383
	<u>          </u>	<u>          </u>

**5. Raising funds****Raising donations and legacies**

	<b>31.12.24</b>	<b>31.12.23</b>
	£	£
Staff costs	95,753	26,269
Other fundraising costs	7,311	10,650
Support costs	70,729	42,337
	<u>          </u>	<u>          </u>
	173,793	79,256
	<u>          </u>	<u>          </u>

**6. Charitable activities costs**

	<b>Direct Costs</b>	<b>Support costs (see note 7)</b>	<b>Totals</b>
	£	£	£
Charitable activities	260,224	131,467	391,691
	<u>          </u>	<u>          </u>	<u>          </u>

**7. Support costs**

	<b>General costs</b>	<b>Governance costs</b>	<b>Totals</b>
	£	£	£
Raising donations and legacies	42,604	28,125	70,729
Charitable activities	126,667	4,800	131,467
	<u>          </u>	<u>          </u>	<u>          </u>
	169,271	32,925	202,196
	<u>          </u>	<u>          </u>	<u>          </u>

**8. Net income/(expenditure)**

Net income/(expenditure) is stated after charging/(crediting):

	<b>31.12.24</b>	<b>31.12.23</b>
	£	£
Depreciation - owned assets	5,319	6,554
Hire of plant and machinery	3,600	7,705
Other operating leases	48,415	45,246
Deficit on disposal of fixed assets	214	3,946
Computer software amortisation	16,709	14,902
	<u>          </u>	<u>          </u>

## ANAPHYLAXIS UK

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**9. Trustees' remuneration and benefits**

There were no trustees' remuneration or other benefits for the year ended 31 December 2024 nor for the year ended 31 December 2023.

**Trustees' expenses**

There were no trustees' expenses paid for the year ended 31 December 2024 nor for the year ended 31 December 2023.

**10. Staff costs**

	<b>31.12.24</b>	<b>31.12.23</b>
	<b>£</b>	<b>£</b>
Wages and salaries	313,432	305,647
	<u>313,432</u>	<u>305,647</u>

The average monthly number of employees during the year was as follows:

	<b>31.12.24</b>	<b>31.12.23</b>
Fundraising	2	1
Charitable activities	7	7
	<u>9</u>	<u>8</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	<b>31.12.24</b>	<b>31.12.23</b>
£60,001 - £70,000	1	-
£70,001 - £80,000	1	1
	<u>2</u>	<u>1</u>

**11. Comparatives for the statement of financial activities**

	<b>Unrestricted fund £</b>	<b>Restricted funds £</b>	<b>Total funds £</b>
<b>Income and endowments from</b>			
Donations and legacies	551,512	-	551,512
Other trading activities	31,202	-	31,202
Investment income	3,383	-	3,383
	<u>586,097</u>	<u>-</u>	<u>586,097</u>
<b>Total</b>			
<b>Expenditure on</b>			
Raising funds	79,256	-	79,256
<b>Charitable activities</b>			
Charitable activities	496,285	-	496,285
Other	3,946	-	3,946

## ANAPHYLAXIS UK

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**11. Comparatives for the statement of financial activities - continued**

	Unrestricted fund £	Restricted funds £	Total funds £
<b>Total</b>	579,487	-	579,487
Net gains on investments	9,471	-	9,471
<b>NET INCOME</b>	16,081	-	16,081
<b>Reconciliation of funds</b>			
Total funds brought forward	613,648	-	613,648
<b>Total funds carried forward</b>	629,729	-	629,729

**12. Intangible fixed assets**

	Computer software £
<b>Cost</b>	
At 1 January 2024	58,302
Additions	18,076
At 31 December 2024	76,378
<b>Amortisation</b>	
At 1 January 2024	20,339
Charge for year	16,709
At 31 December 2024	37,048
<b>Net book value</b>	
At 31 December 2024	39,330
At 31 December 2023	37,963

## ANAPHYLAXIS UK

NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2024

## 13. Tangible fixed assets

	Plant and machinery £
<b>Cost</b>	
At 1 January 2024	25,889
Additions	350
Disposals	(3,115)
At 31 December 2024	23,124
<b>Depreciation</b>	
At 1 January 2024	14,956
Charge for year	5,319
Eliminated on disposal	(2,727)
At 31 December 2024	17,548
<b>Net book value</b>	
At 31 December 2024	5,576
At 31 December 2023	10,933

## 14. Fixed asset investments

	Shares in group undertakings £	Listed investments £	Totals £
<b>Market value</b>			
At 1 January 2024	1	164,295	164,296
Revaluations	-	10,882	10,882
At 31 December 2024	1	175,177	175,178
<b>Net book value</b>			
At 31 December 2024	1	175,177	175,178
At 31 December 2023	1	164,295	164,296

There were no investment assets outside the UK.

Anaphylaxis UK holds the entire £1 share capital of its trading subsidiary Anaphylaxis UK Trading Ltd. The subsidiary began trading on 1 January 2023 and its income for the year to 31 December 2024 was £271,803 (2023 - £289,629). The subsidiary gifts its taxable profit to Anaphylaxis UK and consequently it had no reserves at 31 December 2024 other than its share capital of £1.

Listed fixed asset investments are revalued each year by the external fund managers.

## ANAPHYLAXIS UK

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**15. Stocks**

	<b>31.12.24</b>	<b>31.12.23</b>
	£	£
Finished goods	-	311
	<u>          </u>	<u>          </u>

**16. Debtors: amounts falling due within one year**

	<b>31.12.24</b>	<b>31.12.23</b>
	£	£
Trade debtors	3,890	3,784
Amounts owed by group undertakings	130,512	85,643
VAT	5,571	5,105
Prepayments and accrued income	38,686	45,801
Accrued income	22,915	9,712
	<u>          </u>	<u>          </u>
	<u>201,574</u>	<u>150,045</u>

**17. Creditors: amounts falling due within one year**

	<b>31.12.24</b>	<b>31.12.23</b>
	£	£
Trade creditors	39,262	39,960
Social security and other taxes	7,739	6,625
Accruals and deferred income	12,050	1,948
Accrued expenses	7,905	7,805
	<u>          </u>	<u>          </u>
	<u>66,956</u>	<u>56,338</u>

**18. Movement in funds**

	<b>At 1.1.24</b>	<b>Net movement in funds</b>	<b>At 31.12.24</b>
	£	£	£
<b>Unrestricted funds</b>			
General fund	629,729	76,698	706,427
<b>Restricted funds</b>			
Isle of Man Fund	-	2,138	2,138
	<u>          </u>	<u>          </u>	<u>          </u>
<b>TOTAL FUNDS</b>	<u>629,729</u>	<u>78,836</u>	<u>708,565</u>

## ANAPHYLAXIS UK

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**18. Movement in funds - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	631,514	(565,698)	10,882	76,698
<b>Restricted funds</b>				
Isle of Man Fund	2,138	-	-	2,138
<b>TOTAL FUNDS</b>	<u>633,652</u>	<u>(565,698)</u>	<u>10,882</u>	<u>78,836</u>

**Comparatives for movement in funds**

	At 1.1.23 £	Net movement in funds £	At 31.12.23 £
<b>Unrestricted funds</b>			
General fund	613,648	16,081	629,729
<b>TOTAL FUNDS</b>	<u>613,648</u>	<u>16,081</u>	<u>629,729</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	586,097	(579,487)	9,471	16,081
<b>TOTAL FUNDS</b>	<u>586,097</u>	<u>(579,487)</u>	<u>9,471</u>	<u>16,081</u>



## ANAPHYLAXIS UK

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**18. Movement in funds - continued**

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.23 £	Net movement in funds £	At 31.12.24 £
<b>Unrestricted funds</b>			
General fund	613,648	92,779	706,427
<b>Restricted funds</b>			
Isle of Man Fund	-	2,138	2,138
<b>TOTAL FUNDS</b>	<u>613,648</u>	<u>94,917</u>	<u>708,565</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	1,217,611	(1,145,185)	20,353	92,779
<b>Restricted funds</b>				
Isle of Man Fund	2,138	-	-	2,138
<b>TOTAL FUNDS</b>	<u>1,219,749</u>	<u>(1,145,185)</u>	<u>20,353</u>	<u>94,917</u>

**19. Related party disclosures**

In October 2022 a subsidiary company, Anaphylaxis UK Trading Ltd, was formed. This subsidiary commenced trading in 2023. In the year to 31 December 2024 the subsidiary had income of £271,803 (2023 - £289,629). In accordance with the agreement between the two entities, the whole of Anaphylaxis UK Trading Ltd's taxable profit of £183,240 (2023 - £258,889) was paid to Anaphylaxis UK.

## ANAPHYLAXIS UK

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 DECEMBER 2024**

	31.12.24 £	31.12.23 £
<b>Income and endowments</b>		
<b>Donations and legacies</b>		
Donations - members	25,304	27,638
Memoriam donations	30,718	19,828
Gift aid	37,599	27,636
Community fundraising & events	43,954	46,233
Charitable trusts and major donors	62,300	20,600
Corporate donations	11,862	7,135
Legacies	-	501
Individual membership	41,715	43,876
Professional membership	155	2,443
Other including Google Adwords	107,556	96,733
Income from subsidiary	183,240	258,889
	<hr/>	<hr/>
	544,403	551,512
<b>Other trading activities</b>		
Event income	40,631	15,322
Special project income	37,500	12,380
Other sundry income	361	-
Corporate sponsorship	-	3,500
	<hr/>	<hr/>
	78,492	31,202
<b>Investment income</b>		
Dividends and interest rec'd	10,757	3,383
	<hr/>	<hr/>
<b>Total incoming resources</b>	633,652	586,097
<b>Expenditure</b>		
<b>Raising donations and legacies</b>		
Wages	95,753	26,269
Other fundraising costs	7,311	10,650
	<hr/>	<hr/>
	103,064	36,919
<b>Charitable activities</b>		
Wages	154,125	184,957
Shop and activity purchases	85,378	92,745
Contractor costs	10,048	19,695
Conference and events	5,370	1,636
Special projects	5,303	6,343
	<hr/>	<hr/>
	260,224	305,376

This page does not form part of the statutory financial statements

## ANAPHYLAXIS UK

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 DECEMBER 2024**

	<b>31.12.24</b>	<b>31.12.23</b>
	<b>£</b>	<b>£</b>
<b>Charitable activities</b>		
<b>Other</b>		
Loss on sale of tangible fixed assets	214	3,946
<b>Support costs</b>		
<b>General costs</b>		
Wages	35,429	67,598
Rent and rates	3,600	7,705
Computer and software costs	48,415	45,246
Telephone	1,372	5,983
Travel and subsistence	3,188	2,150
Recruitment and redundancy	18,979	421
Staff training	5,971	2,034
Office expenses	229	1,091
Stationery and printing	840	620
Postage and carriage	591	246
Professional fees	5,572	2,119
Website costs	1,583	1,524
Insurance	1,981	2,018
Irrecoverable VAT	16,506	22,745
Sundry	357	10,627
Bank charges	2,631	6,340
Plant and machinery	22,027	21,456
	<u>169,271</u>	<u>199,923</u>
<b>Governance costs</b>		
Wages	28,125	26,823
Accountancy and legal fees	4,800	6,500
	<u>32,925</u>	<u>33,323</u>
Total resources expended	<u>565,698</u>	<u>579,487</u>
<b>Net income</b>	<u><u>67,954</u></u>	<u><u>6,610</u></u>

This page does not form part of the statutory financial statements